Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas
Status:
Recruiting
Trial end date:
2029-10-30
Target enrollment:
Participant gender:
Summary
Background:
Neuroendocrine neoplasms (NENs) are rare cancers in the gastrointestinal tract, pancreas,
lungs, adrenal glands, and other areas of the body. Many of these cancers have a high risk of
relapse and a low chance of survival. Better treatments are needed.
Objective:
To test a new drug, ADCT-701, in people with NENs.
Eligibility:
Adults aged 18 and older with NENs.
Design:
Participants will be screened. They will have a physical exam with blood and urine tests.
They will have imaging scans and tests of heart functioning. Their ability to perform normal
daily activities will be tested. A biopsy may be needed: A sample of tissue will be removed
from the tumor.
ADCT-701 is given through a tube attached to a needle inserted into a vein in the arm.
Participants will receive the drug treatment on the first day of 21-day treatment cycles.
They will visit the clinic a total of 10 times during the first two cycles. After that, they
will visit the clinic 2 times during each cycle. Imaging scans, blood draws, heart function
tests, and other tests will be repeated during study visits. Each visit will last up to 8
hours.
Participants may continue receiving treatment with the study drug for up to 2 years.
After treatment ends, participants will have follow-up clinic visits 4 times in 4 months.
They will have a physical exam, with heart and blood tests, at each visit. After that, they
will have follow-up clinic visits every 9 weeks; these visits will include imaging scans.
Follow-up visits will continue for up to 5 years after treatment began....